# Fenfluramine in CDKL5 Deficiency Disorder (CDD)

> **NCT03861871** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 7 (actual)

## Conditions studied

- CDD

## Interventions

- **DRUG:** Fenfluramine Hydrochloride

## Key facts

- **NCT ID:** NCT03861871
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-29
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-10-24
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861871, "Fenfluramine in CDKL5 Deficiency Disorder (CDD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03861871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*